13 results on '"Irene van Heuvel"'
Search Results
2. Data from Detection of Aneuploidy in Cerebrospinal Fluid from Patients with Breast Cancer Can Improve Diagnosis of Leptomeningeal Metastases
- Author
-
Saskia M. Wilting, Joost L.M. Jongen, Stefan Sleijfer, Ellen Heitzer, Eric M.J. Bindels, Johan M. Kros, Peter A.E. Sillevis Smitt, Martin J. van den Bent, Irene van Heuvel, Vanja de Weerd, John W.M. Martens, Agnes Jager, Teoman Deger, and Lindsay Angus
- Abstract
Purpose:Detection of leptomeningeal metastasis is hampered by limited sensitivities of currently used techniques: MRI and cytology of cerebrospinal fluid (CSF). Detection of cell-free tumor DNA in CSF has been proposed as a tumor-specific candidate to detect leptomeningeal metastasis at an earlier stage. The aim of this study was to investigate mutation and aneuploidy status in CSF-derived cell-free DNA (cfDNA) of patients with breast cancer with a clinical suspicion of leptomeningeal metastasis.Experimental Design:cfDNA was isolated from stored remnant CSF and analyzed by targeted next-generation sequencing (NGS; n = 30) and the modified fast aneuploidy screening test-sequencing system (mFAST-SeqS; n = 121). The latter method employs selective amplification of long interspaced nuclear elements sequences that are present throughout the genome and allow for fast and cheap detection of aneuploidy. We compared these results with the gold standard to diagnose leptomeningeal metastasis: cytology.Results:Leptomeningeal metastasis was cytology proven in 13 of 121 patients. Low DNA yields resulted in insufficient molecular coverage of NGS for the majority of samples (success rate, 8/30). The mFAST-SeqS method, successful in 112 of 121 (93%) samples, detected genome-wide aneuploidy in 24 patients. Ten of these patients had cytology-proven leptomeningeal metastasis; 8 additional patients were either concurrently diagnosed with central nervous system metastases by radiological means or developed these soon after the lumbar puncture. The remaining six cases were suspected of leptomeningeal metastasis, but could not be confirmed by cytology or imaging. Aneuploidy was associated with development of leptomeningeal metastasis and significantly worse overall survival.Conclusions:Aneuploidy in CSF-derived cfDNA may provide a promising biomarker to improve timely detection of leptomeningeal metastasis.
- Published
- 2023
3. Supplementary Data from Detection of Aneuploidy in Cerebrospinal Fluid from Patients with Breast Cancer Can Improve Diagnosis of Leptomeningeal Metastases
- Author
-
Saskia M. Wilting, Joost L.M. Jongen, Stefan Sleijfer, Ellen Heitzer, Eric M.J. Bindels, Johan M. Kros, Peter A.E. Sillevis Smitt, Martin J. van den Bent, Irene van Heuvel, Vanja de Weerd, John W.M. Martens, Agnes Jager, Teoman Deger, and Lindsay Angus
- Abstract
Supplementary Tables
- Published
- 2023
4. Detection of aneuploidy in cerebrospinal fluid from patients with breast cancer can improve diagnosis of leptomeningeal metastases
- Author
-
Martin J. van den Bent, Irene van Heuvel, John W.M. Martens, Peter A. E. Sillevis Smitt, Lindsay Angus, Ellen Heitzer, Agnes Jager, Vanja de Weerd, Joost L.M. Jongen, Saskia M Wilting, Stefan Sleijfer, Teoman Deger, Eric M.J. Bindels, Johan M. Kros, Medical Oncology, Neurology, Pathology, and Hematology
- Subjects
Cancer Research ,medicine.medical_specialty ,DNA Mutational Analysis ,Aneuploidy ,Breast Neoplasms ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Cerebrospinal fluid ,SDG 3 - Good Health and Well-being ,Cytology ,Biomarkers, Tumor ,medicine ,Humans ,Stage (cooking) ,medicine.diagnostic_test ,Lumbar puncture ,business.industry ,Liquid Biopsy ,Disease Management ,High-Throughput Nucleotide Sequencing ,Gold standard (test) ,Middle Aged ,Prognosis ,medicine.disease ,Combined Modality Therapy ,Magnetic Resonance Imaging ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,Mutation ,Biomarker (medicine) ,Female ,Radiology ,business ,Cell-Free Nucleic Acids ,Meningeal Carcinomatosis ,030217 neurology & neurosurgery - Abstract
Purpose: Detection of leptomeningeal metastasis is hampered by limited sensitivities of currently used techniques: MRI and cytology of cerebrospinal fluid (CSF). Detection of cell-free tumor DNA in CSF has been proposed as a tumor-specific candidate to detect leptomeningeal metastasis at an earlier stage. The aim of this study was to investigate mutation and aneuploidy status in CSF-derived cell-free DNA (cfDNA) of patients with breast cancer with a clinical suspicion of leptomeningeal metastasis. Experimental Design: cfDNA was isolated from stored remnant CSF and analyzed by targeted next-generation sequencing (NGS; n = 30) and the modified fast aneuploidy screening test-sequencing system (mFAST-SeqS; n = 121). The latter method employs selective amplification of long interspaced nuclear elements sequences that are present throughout the genome and allow for fast and cheap detection of aneuploidy. We compared these results with the gold standard to diagnose leptomeningeal metastasis: cytology. Results: Leptomeningeal metastasis was cytology proven in 13 of 121 patients. Low DNA yields resulted in insufficient molecular coverage of NGS for the majority of samples (success rate, 8/30). The mFAST-SeqS method, successful in 112 of 121 (93%) samples, detected genome-wide aneuploidy in 24 patients. Ten of these patients had cytology-proven leptomeningeal metastasis; 8 additional patients were either concurrently diagnosed with central nervous system metastases by radiological means or developed these soon after the lumbar puncture. The remaining six cases were suspected of leptomeningeal metastasis, but could not be confirmed by cytology or imaging. Aneuploidy was associated with development of leptomeningeal metastasis and significantly worse overall survival. Conclusions: Aneuploidy in CSF-derived cfDNA may provide a promising biomarker to improve timely detection of leptomeningeal metastasis.
- Published
- 2021
5. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma
- Author
-
Anja Gijtenbeek, Vassilis Golfinopoulos, Michael Weller, Sarah Pascoe, Roger Stupp, Sara Erridge, Irene van Heuvel, Marc Sanson, Winand N.M. Dinjens, Hendrikus J. Dubbink, Warren P. Mason, David Brachman, Martin J. van den Bent, Robert B. Jenkins, Peter Hau, Wolfgang Wick, Thierry Lesimple, Susan Clenton, Matthew E. Griffin, Jean Francais Baurain, Brigitta G. Baumert, Sanjeev Gill, Roelien H. Enting, Walter Taal, Damien C. Weber, Kenneth Aldape, Pieter Wesseling, Roberta Rudà, Catherine McBain, Helen Wheeler, Sarah Nuyens, Johan M. Kros, Anna K. Nowak, Paul Clement, Frédéric Dhermain, Thierry Gorlia, Ulrich Herrlinger, Olivier Chinot, Jaap C. Reijneveld, Alba A. Brandes, Michael A. Vogelbaum, CCA - Cancer Treatment and quality of life, Neurology, Amsterdam Neuroscience - Systems & Network Neuroscience, Amsterdam Neuroscience - Brain Imaging, Pathology, Erasmus MC other, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, and Radiotherapie
- Subjects
Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,PROCARBAZINE ,IDH2 MUTATIONS ,Other Research Donders Center for Medical Neuroscience [Radboudumc 0] ,GLIOBLASTOMA ,OLIGODENDROGLIAL TUMORS ,Procarbazine ,Article ,03 medical and health sciences ,All institutes and research themes of the Radboud University Medical Center ,0302 clinical medicine ,EUROPEAN ORGANIZATION ,Internal medicine ,medicine ,BRAIN-TUMOR GROUP ,VINCRISTINE ,610 Medicine & health ,Chemotherapy ,Temozolomide ,Intention-to-treat analysis ,III TRIAL ,Performance status ,business.industry ,Hazard ratio ,LOW-GRADE GLIOMA ,General Medicine ,CHEMOTHERAPY ,Interim analysis ,Surgery ,Radiation therapy ,030220 oncology & carcinogenesis ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Item does not contain fulltext BACKGROUND: The role of temozolomide chemotherapy in newly diagnosed 1p/19q non-co-deleted anaplastic gliomas, which are associated with lower sensitivity to chemotherapy and worse prognosis than 1p/19q co-deleted tumours, is unclear. We assessed the use of radiotherapy with concurrent and adjuvant temozolomide in adults with non-co-deleted anaplastic gliomas. METHODS: This was a phase 3, randomised, open-label study with a 2 x 2 factorial design. Eligible patients were aged 18 years or older and had newly diagnosed non-co-deleted anaplastic glioma with WHO performance status scores of 0-2. The randomisation schedule was generated with the electronic EORTC web-based ORTA system. Patients were assigned in equal numbers (1:1:1:1), using the minimisation technique, to receive radiotherapy (59.4 Gy in 33 fractions of 1.8 Gy) alone or with adjuvant temozolomide (12 4-week cycles of 150-200 mg/m(2) temozolomide given on days 1-5); or to receive radiotherapy with concurrent temozolomide 75 mg/m(2) per day, with or without adjuvant temozolomide. The primary endpoint was overall survival adjusted for performance status score, age, 1p loss of heterozygosity, presence of oligodendroglial elements, and MGMT promoter methylation status, analysed by intention to treat. We did a planned interim analysis after 219 (41%) deaths had occurred to test the null hypothesis of no efficacy (threshold for rejection p
- Published
- 2017
6. Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics
- Author
-
Winand N.M. Dinjens, Jacoline E C Bromberg, Carin C.D. van der Rijt, Peter A. E. Sillevis Smitt, Irene van Heuvel, Agnes A. A. C. M. Wertenbroek, Johan M. Kros, Walter Taal, Martin J. van den Bent, Neurology, Medical Oncology, and Pathology
- Subjects
Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Vincristine ,medicine.medical_treatment ,Oligodendroglioma ,Antineoplastic Agents ,Procarbazine ,Lomustine ,Internal medicine ,medicine ,Humans ,Oligodendroglial Tumor ,Survival analysis ,Retrospective Studies ,Chemotherapy ,business.industry ,Brain Neoplasms ,Middle Aged ,medicine.disease ,Survival Analysis ,Surgery ,Tumor Burden ,Radiation therapy ,Treatment Outcome ,Neurology ,Disease Progression ,Drug Therapy, Combination ,Female ,Neurology (clinical) ,business ,medicine.drug ,Follow-Up Studies - Abstract
We treated patients with newly diagnosed and large low-grade oligodendroglial tumors with upfront procarbazine, CCNU and vincristine (PCV) in order to delay radiotherapy. Patients were treated with PCV for a maximum of 6 cycles. The response to treatment was defined according to the RANO criteria; in addition change over time of mean tumor diameters (growth kinetics) was calculated. Thirty-two patients were treated between 1998 and 2006, 18 of which were diagnosed with 1p/19q co-deleted tumors. Median follow-up duration was 8 years (range 0.5–13 years). The median overall survival (mOS) was 120 months and the median progression-free survival (mPFS) was 46 months. Growth kinetics showed an ongoing decrease of the mean tumor diameter after completion of chemotherapy, during a median time of 35 months, but an increase of the mean tumor diameter did not herald progression as detected by RANO criteria. 1p/19q co-deletion was associated with a significant increase in OS (mOS 83 months versus not reached for codeleted tumors; p = 0.003)) and PFS (mPFS 35 months versus 67 months for codeleted tumors; p = 0.024). Patients with combined 1p/19q loss had a 10 year PFS of 34 % and the radiotherapy in these patients was postponed for a median period of more than 6 years. This long-term follow-up study indicates that upfront PCV chemotherapy is associated with long PFS and OS and delays radiotherapy for a considerable period of time in patients with low-grade oligodendroglial tumors, in particular with combined 1p/19q loss.
- Published
- 2015
7. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
- Author
-
HM Oosterkamp, Jan Buter, Annemiek M E Walenkamp, Hendrikus J. Dubbink, Irene van Heuvel, Franchette W P J van den Berkmortel, Filip de Vos, Dolf Boerman, Rob L. H. Jansen, Bronno van der Holt, Laurens V. Beerepoot, Martin J. van den Bent, Dieta Brandsma, Winand N.M. Dinjens, Martin J B Taphoorn, Jacoline E C Bromberg, Roelien H. Enting, René M. Vernhout, Monique Hanse, Aafke H. Honkoop, Walter Taal, Guided Treatment in Optimal Selected Cancer Patients (GUTS), RS: GROW - Oncology, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), Neurology, Pathology, Erasmus MC other, Hematology, Medical oncology, and CCA - Innovative therapy
- Subjects
Male ,IRINOTECAN ,medicine.medical_treatment ,Administration, Oral ,Phases of clinical research ,Gastroenterology ,law.invention ,Randomized controlled trial ,Lomustine ,law ,Infusions, Intravenous ,Brain Neoplasms ,Middle Aged ,MALIGNANT GLIOMA ,Bevacizumab ,Drug Combinations ,Editorial ,Oncology ,SURVIVAL ,Drug Therapy, Combination ,Female ,NEWLY-DIAGNOSED GLIOBLASTOMA ,medicine.drug ,RADIOTHERAPY ,Adult ,medicine.medical_specialty ,Adolescent ,Maximum Tolerated Dose ,Antibodies, Monoclonal, Humanized ,Disease-Free Survival ,Drug Administration Schedule ,II TRIAL ,Young Adult ,Internal medicine ,medicine ,Humans ,Neoplasm Invasiveness ,Neoplasm Staging ,Chemotherapy ,Intention-to-treat analysis ,Dose-Response Relationship, Drug ,business.industry ,ADJUVANT TEMOZOLOMIDE ,EFFICACY ,Survival Analysis ,Surgery ,Irinotecan ,PATTERNS ,Neoplasm Recurrence, Local ,Glioblastoma ,business ,Chemoradiotherapy ,RESPONSE ASSESSMENT ,Follow-Up Studies - Abstract
BACKGROUND: Treatment options for recurrent glioblastoma are scarce, with second-line chemotherapy showing only modest activity against the tumour. Despite the absence of well controlled trials, bevacizumab is widely used in the treatment of recurrent glioblastoma. Nonetheless, whether the high response rates reported after treatment with this drug translate into an overall survival benefit remains unclear. We report the results of the first randomised controlled phase 2 trial of bevacizumab in recurrent glioblastoma.METHODS: The BELOB trial was an open-label, three-group, multicentre phase 2 study undertaken in 14 hospitals in the Netherlands. Adult patients (≥18 years of age) with a first recurrence of a glioblastoma after temozolomide chemoradiotherapy were randomly allocated by a web-based program to treatment with oral lomustine 110 mg/m(2) once every 6 weeks, intravenous bevacizumab 10 mg/kg once every 2 weeks, or combination treatment with lomustine 110 mg/m(2) every 6 weeks and bevacizumab 10 mg/kg every 2 weeks. Randomisation of patients was stratified with a minimisation procedure, in which the stratification factors were centre, Eastern Cooperative Oncology Group performance status, and age. The primary outcome was overall survival at 9 months, analysed by intention to treat. A safety analysis was planned after the first ten patients completed two cycles of 6 weeks in the combination treatment group. This trial is registered with the Nederlands Trial Register (www.trialregister.nl, number NTR1929).FINDINGS: Between Dec 11, 2009, and Nov 10, 2011, 153 patients were enrolled. The preplanned safety analysis was done after eight patients had been treated, because of haematological adverse events (three patients had grade 3 thrombocytopenia and two had grade 4 thrombocytopenia) which reduced bevacizumab dose intensity; the lomustine dose in the combination treatment group was thereafter reduced to 90 mg/m(2). Thus, in addition to the eight patients who were randomly assigned to receive bevacizumab plus lomustine 110 mg/m(2), 51 patients were assigned to receive bevacizumab alone, 47 to receive lomustine alone, and 47 to receive bevacizumab plus lomustine 90 mg/m(2). Of these patients, 50 in the bevacizumab alone group, 46 in the lomustine alone group, and 44 in the bevacizumab and lomustine 90 mg/m(2) group were eligible for analyses. 9-month overall survival was 43% (95% CI 29-57) in the lomustine group, 38% (25-51) in the bevacizumab group, 59% (43-72) in the bevacizumab and lomustine 90 mg/m(2) group, 87% (39-98) in the bevacizumab and lomustine 110 mg/m(2) group, and 63% (49-75) for the combined bevacizumab and lomustine groups. After the reduction in lomustine dose in the combination group, the combined treatment was well tolerated. The most frequent grade 3 or worse toxicities were hypertension (13 [26%] of 50 patients in the bevacizumab group, three [7%] of 46 in the lomustine group, and 11 [25%] of 44 in the bevacizumab and lomustine 90 mg/m(2) group), fatigue (two [4%], four [9%], and eight [18%]), and infections (three [6%], two [4%], and five [11%]). At the time of this analysis, 144/148 (97%) of patients had died and three (2%) were still on treatment.INTERPRETATION: The combination of bevacizumab and lomustine met prespecified criteria for assessment of this treatment in further phase 3 studies. However, the results in the bevacizumab alone group do not justify further studies of this treatment.FUNDING: Roche Nederland and KWF Kankerbestrijding.
- Published
- 2014
8. Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study
- Author
-
Irene van Heuvel, Peter A. E. Sillevis Smitt, Johan M. Kros, Joyce M. W. Segers-van Rijn, Walter Taal, Martin J. van den Bent, Jacoline E C Bromberg, Carin C.D. van der Rijt, Neurology, Pathology, and Medical Oncology
- Subjects
Male ,Oncology ,Cancer Research ,Dose dense temozolomide ,Medicine & Public Health ,Brain Neoplasms ,Glioma ,Middle Aged ,1p ,Dacarbazine ,Treatment Outcome ,Neurology ,Tolerability ,Female ,medicine.drug ,Adult ,medicine.medical_specialty ,19q ,Oligodendroglioma ,Clinical Neurology ,Astrocytoma ,Recurrent Glioma ,Brain tumors ,Disease-Free Survival ,Drug Administration Schedule ,Internal medicine ,Temozolomide ,medicine ,Humans ,Chemotherapy ,Progression-free survival ,Antineoplastic Agents, Alkylating ,neoplasms ,Aged ,Retrospective Studies ,business.industry ,medicine.disease ,nervous system diseases ,Surgery ,Regimen ,Clinical Study ,Neurology (clinical) ,Neoplasm Recurrence, Local ,Glioblastoma ,business - Abstract
Alternative temozolomide regimens have been proposed to overcome O(6)-methylguanine-DNA methyltransferase mediated resistance. We investigated the efficacy and tolerability of 1 week on/1 week off temozolomide (ddTMZ) regimen in a cohort of patients treated with ddTMZ between 2005 and 2011 for the progression of a glioblastoma during or after chemo-radiation with temozolomide or a recurrence of another type of glioma after radiotherapy and at least one line of chemotherapy. Patients received ddTMZ at 100-150 mg/m(2)/d (days 1-7 and 15-21 in cycles of 28-days). All patients had a contrast enhancing lesion on MRI and the response was assessed by MRI using the RANO criteria; complete and partial responses were considered objective responses. Fifty-three patients were included. The median number of cycles of ddTMZ was 4 (range 1-12). Eight patients discontinued chemotherapy because of toxicity. Two of 24 patients with a progressive glioblastoma had an objective response; progression free survival at 6 months (PFS-6) in glioblastoma was 29%. Three of the 16 patients with a recurrent WHO grade 2 or 3 astrocytoma or oligodendroglioma or oligo-astrocytoma without combined 1p and 19q loss had an objective response and PFS-6 in these patients was 38%. Four out of the 12 evaluable patients with a recurrent WHO grade 2 or 3 oligodendroglioma or oligo-astrocytoma with combined 1p and 19q loss had an objective response; PFS-6 in these patients was 62%. This study indicates that ddTMZ is safe and effective in recurrent glioma, despite previous temozolomide and/or nitrosourea chemotherapy. Our data do not suggest superior efficacy of this schedule as compared to the standard day 1-5 every 4 weeks schedule.
- Published
- 2012
9. First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response
- Author
-
Jacoline E C Bromberg, Irene van Heuvel, Winand N.M. Dinjens, Walter Taal, Martin J. van den Bent, Willem Boogerd, Floris H. Groenendijk, Tjeerd J. Postma, Johan M. Kros, Hendrikus J. Dubbink, Bronno van der Holt, Chris B.L. Zonnenberg, Ronald van Marion, Peter A. E. Sillevis Smitt, Bernard A. Zonnenberg, J.M.M. Gijtenbeek, Mathilde C.M. Kouwenhoven, Surgery, Neurology, CCA - Innovative therapy, Pathology, and Hematology
- Subjects
Male ,Oncology ,Cancer Research ,Trisomy ,Neuroinformatics [DCN 3] ,Gene mutation ,Polymerase Chain Reaction ,Immunoenzyme Techniques ,Promoter Regions, Genetic ,Brain Neoplasms ,Astrocytoma ,Radiotherapy Dosage ,DNA, Neoplasm ,Middle Aged ,Chemotherapy regimen ,Isocitrate Dehydrogenase ,Dacarbazine ,Survival Rate ,Treatment Outcome ,Chromosomes, Human, Pair 1 ,Female ,Chromosome Deletion ,medicine.drug ,Adult ,medicine.medical_specialty ,Clinical Investigations ,Biology ,O(6)-Methylguanine-DNA Methyltransferase ,Glioma ,Internal medicine ,Biomarkers, Tumor ,Temozolomide ,medicine ,Humans ,Antineoplastic Agents, Alkylating ,neoplasms ,Neoplasm Staging ,O-6-methylguanine-DNA methyltransferase ,DNA Methylation ,medicine.disease ,Mutation ,Cancer research ,Neurology (clinical) ,Oligodendroglioma ,Tumor Suppressor Protein p53 ,Chromosomes, Human, Pair 19 ,Progressive disease ,Follow-Up Studies - Abstract
Diffuse infiltrating low-grade glioma (LGG; WHO grade II tumors) constitute approximately 10–20% of primary brain tumors in adults and primarily occur in young adults.1 The majority of LGGs are low-grade diffuse astrocytomas (LGAs). Although LGAs are usually well-differentiated and slow-growing tumors, no curative treatment exists. In most patients, progression into higher grade tumors (WHO grade III–IV) occurs during the course of this ultimately fatal disease. The standard treatment for LGA is surgical resection and radiotherapy (RT). Although the role of early surgery and extent of resection has never been proven in randomized studies, retrospective studies suggest that extensive resection may improve the outcome.2 Radiotherapy is usually offered to patients with symptomatic and/or progressive disease or to patients with poor prognostic factors.3,4 As LGAs are less sensitive to chemotherapy than low-grade oligodendroglioma, chemotherapy is currently primarily used for recurrent disease. Temozolomide (TMZ) has become the mainstay of treatment in this setting. Only a few studies, however, have systematically examined the effect of TMZ in progressive LGA after surgery and RT.5,6 These studies are difficult to interpret because they included heterogeneous groups of patients, with both low-grade lesions and de-differentiated tumors, and with a variety of prior treatments. Furthermore, there are limited data on molecular correlates with the outcome to chemotherapy in patients with progressive LGA after RT. At the molecular level, LGAs frequently show TP53 mutations, isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) gene mutations, trisomy of chromosome 7, and O6-methylguanine-methyltransferase (MGMT) promoter methylation. It is at present unclear whether the different molecular subtypes respond differently to TMZ. TP53 mutations are found in 39–43% of the patients with LGA.7,8 Recent studies have shown that 90% of LGA have mutations in the IDH1 gene and that patients with IDH1 mutations have a better survival.9,10 Additionally, IDH1 mutations were found not to predict the outcome in recurrent LGA to TMZ treatment.10 Polysomy of chromosome 7 was observed in 66% of LGAs and correlated with survival.11 The nuclear enzyme MGMT is a key factor in the resistance against alkylating and methylating chemotherapy. Clinical evidence suggests that the methylation of the MGMT gene promoter (mMGTM) is related to the outcome to TMZ treatment in newly diagnosed glioblastoma.12 However, data on mMGMT in LGA are scarce, and the relevance of MGMT promoter methylation of recurrent LGA in the response to TMZ is unclear. We conducted a retrospective multicenter study in a cohort of patients with LGA treated with TMZ at the time of progression into a high-grade glioma after prior RT to evaluate the therapeutic efficacy of the standard TMZ regimen with respect to response, survival, and toxicity. Outcome was correlated with 19q loss, trisomy of chromosome 7, MGMT promotor methylation, and IDH1 and TP53 mutations.
- Published
- 2010
10. AT-56TREATMENT OF LARGE LOW-GRADE OLIGODENDROGLIAL TUMORS WITH UPFRONT PROCARBAZINE, LOMUSTINE, AND VINCRISTINE CHEMOTHERAPY WITH LONG FOLLOW-UP: A RETROSPECTIVE COHORT STUDY WITH GROWTH KINETICS
- Author
-
Irene van Heuvel, Martin J. van den Bent, Karin van der Rijt, Winand N.M. Dinjens, Walter Taal, Johan M. Kros, Jacoline E C Bromberg, Peter A. E. Sillevis Smitt, and Agnes A. A. C. M. Wertenbroek
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Vincristine ,Adult Clinical Trials ,business.industry ,Retrospective cohort study ,Lomustine ,Procarbazine ,medicine.disease ,Chemotherapy regimen ,Surgery ,Internal medicine ,medicine ,Oligodendroglial Tumor ,Neurology (clinical) ,Progression-free survival ,Oligodendroglioma ,business ,medicine.drug - Abstract
PURPOSE: We treated patients with newly diagnosed and large low-grade oligodendroglial tumors with upfront procarbazine, lomustine (CCNU) and vincristine (PCV) in our institution in order to delay RT. We now report long term follow-up on a cohort of patients treated between 1998 and 2006. METHODS: Patients were treated with PCV in cycles of 6 weeks, for a maximum of 6 cycles. Central pathology review, genotyping on 1p/19q loss and immunohistochemistry on the IDH1 mutational status and MIB-1 labeling was performed. The response to treatment was defined according to the RANO criteria; in addition change over time of mean tumor diameters (growth kinetics) was calculated. RESULTS: Thirty-two patients were treated, 18 of which were diagnosed with 1p/19q co-deleted tumors. Median follow-up duration was 8 years. The median overall survival (OS) was 120 months and the median progression-free survival (PFS) was 46 months. Growth kinetics showed an ongoing decrease of the mean tumor diameter after completion of chemotherapy, during a median time of 35 months (range 5-136 months), but an increase of the mean tumor diameter did not herald progression as detected by RANO criteria. 1p/19q co-deletion was associated with a significant increase in OS (median OS 83 months versus not reached for codeleted tumors; p = 0.003)) and PFS (median PFS 35 months versus 67 months for codeleted tumors; p = 0.024). Patients with combined 1p/19q loss had a 10 year PFS of 34% and the radiotherapy in these patients was postponed for a median period of more than 6 years. CONCLUSION: This long-term follow-up study indicates that upfront PCV chemotherapy is associated with long PFS and OS and delays radiotherapy for a considerable period of time in patients with low-grade oligodendroglial tumors, in particular with combined 1p/19q loss.
- Published
- 2014
11. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine and vincristine
- Author
-
Leendert H. J. Looijenga, Johan M. Kros, Carin D. D. van der Rijt, Hein G. de Bruin, Elize M. Biemond-ter Stege, Irene van Heuvel, Roelien H. Enting, Peter A. E. Sillevis Smitt, Martin J. van den Bent, Neurology, Pathology, Radiology & Nuclear Medicine, and Medical Oncology
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Vincristine ,Oligoastrocytoma ,medicine.medical_treatment ,Oligodendroglioma ,Antineoplastic Agents ,Astrocytoma ,Procarbazine ,Polymerase Chain Reaction ,Lomustine ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Medicine ,In Situ Hybridization, Fluorescence ,Retrospective Studies ,Chemotherapy ,Brain Neoplasms ,business.industry ,Middle Aged ,medicine.disease ,Immunohistochemistry ,Magnetic Resonance Imaging ,Chemotherapy regimen ,Surgery ,Radiation therapy ,Oncology ,Chromosomes, Human, Pair 1 ,Female ,Radiology ,Tumor Suppressor Protein p53 ,business ,Chromosomes, Human, Pair 19 ,medicine.drug - Abstract
BACKGROUND: Anaplastic oligodendroglioma (OD) tumors, especially those with the combined loss of the short arm of chromosome 1 (1p) and the long arm of chromosome 19 (19q), are sensitive to chemotherapy. Only limited data are available on the role of chemotherapy in low-grade OD. The authors retrospectively studied the outcome of the procarbazine, lomustine, and vincristine (PCV) chemotherapy regimen in a group of 16 patients with newly diagnosed OD and 5 patients with recurrent low-grade OD. METHODS: Two groups of patients were studied: newly diagnosed patients with large OD and mixed oligoastrocytomas (OA) and patients with recurrent OD and OA after radiotherapy who still showed nonenhancing tumors. Treatment consisted of standard PCV chemotherapy. In the newly diagnosed and responding patients, radiotherapy was withheld until the time of disease recurrence. Responses were assessed by T2-weighted magnetic resonance image (MRI) scans. Loss of chromosome 1p and 19q was assessed using fluorescent in situ hybridization with locus-specific probes. RESULTS: Three of five patients with recurrent tumors responded. Thirteen of the 16 newly diagnosed patients showed evidence of response. The median time to disease progression in this group was >24 months. Only one of these patients experienced disease progression while receiving chemotherapy. Several patients showed a signficant clinical improvement despite only a modest improvement of the tumor on the MRI scans. Even patients without loss of 1p or 19q showed satisfactory responses. No TP53 mutations were found. CONCLUSIONS: Newly diagnosed patients with OD tumors, with or without loss of 1p/19q, responded to PCV chemotherapy. Up-front chemotherapy may be indicated especially for patients with large tumors. MRI scans were of limited value for the assessment of response. A Phase III trial should be initiated to compare radiotherapy with chemotherapy.
- Published
- 2005
12. A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study
- Author
-
Irene van Heuvel, Jacoline E C Bromberg, Rob L. H. Jansen, Laurens V. Beerepoot, René M. Vernhout, Martin J. van den Bent, Dieta Brandsma, Johan M. Kros, HM Oosterkamp, Marion Smits, Jan Buter, Filip de Vos, Franchette W P J van den Berkmortel, Bronno van der Holt, Walter Taal, Aafke H. Honkoop, Monique Hanse, Annemiek M E Walenkamp, and Dolf Boerman
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Bevacizumab ,business.industry ,Recurrent glioblastoma ,Phases of clinical research ,Lomustine ,Internal medicine ,medicine ,Single agent ,Nuclear medicine ,business ,medicine.drug - Abstract
2001 Background: Bevacizumab (BEV) is widely used in recurrent glioblastoma, alone or in combination with other agents. There is however no well-controlled trial to support the use for this indication. Methods: In a three-arm Dutch multicenter randomized phase II study (NTR 1929) patients were assigned to either BEV 10 mg/kg iv every 2 weeks, BEV 10 mg/kg iv every 2 weeks and 110 mg/m2 lomustine every 6 weeks, or lomustine 110 mg/m2every 6 weeks. Eligible were patients with histologically proven glioblastoma, with a first recurrence after chemo-irradiation with temozolomide, having concluded radiotherapy more than 3 months ago, with adequate bone marrow, renal and hepatic function, and WHO performance status (PS) 0-2. Primary endpoint was 9 months overall survival (OS); P0 was set at 35% and P1 at 55%. Progression was defined using RANO criteria. A safety review after the first 10 patients in the combination arm was preplanned. Results: Between December 2009 and November 2011, 153 patients were enrolled of whom 148 were considered eligible. Median age was 57 years (range, 24-77) and median WHO PS was 1. With respect to prognostic factors groups were well balanced. After review of the safety cohort the dosage lomustine in the combination arm was lowered to 90 mg/m2 because of hematological toxicity (predominantly thrombocytopenia without symptoms). At this lower lomustine dose level the combination treatment was in general well tolerated. Outcome: see Table. Conclusions: In this first well-controlled study on BEV in recurrent glioblastoma with a primary OS endpoint, combination treatment with bevacizumab and lomustine met the prespecified criterion for further investigation in clinical trials, whereas both drugs given as single agent failed to meet this criterion. Clinical trial information: NTR1929. [Table: see text]
- Published
- 2013
13. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
- Author
-
Elize M. Biemond-ter Stege, Johan M. Kros, Hein G. de Bruin, R. H. Enting, Irene van Heuvel, Leendert H. J. Looijenga, Carin D. D. van der Rijt, Peter A. E. Sillevis Smitt, and Martin J. van den Bent
- Published
- 2005
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.